Your Messages Inbox
Most Viewed Abstracts
1. Report Shows Shift in Starting Salaries for Physicians 2. 2008 Exclusive Survey—Earnings: Good news for primary care income 3. Medicare pay-for-reporting effort draws fire from frustrated doctors 4. Debunking Myths in the US Healthcare System 5. Statins and cancer risk
Your Article Summary
See Latest Articles
Shire plc, the global specialty biopharmaceutical company, today announced results from a Phase 3b study that found VYVANSE CII demonstrated significant efficacy at 14 hours after administration during a simulated workplace environment study in adults with Attention Deficit Hyperactivity Disorder. VYVANSE is the first approved stimulant for adults with ADHD to be evaluated in this setting, and these data were presented today at the 49th annual New Clinical Drug Evaluation Unit meeting in Hollywood, FL. VYVANSE is currently approved by the US Food and Drug Administration for the treatment of ADHD in children age 6 to 12 years and in adults with ADHD.
Today in Major Studies...keeping you current
Receive free subspecialty "5-minute updates" via email
The INFUSE Morphine Study: Use of Recombinant Human Hyaluronidase (rHuPH20) to Enhance the Absorption of Subcutaneously Administered Morphine in Patients with Advanced Illness
Journal of Pain and Symptom Management, 10/13/09
Psychopharmacology Curriculum Field Test
Academic Psychiatry, 10/16/09
The influence of porosity changes in human epidermal membrane during iontophoresis on the permeability enhancement of a model peptide
Drug Development and Industrial Pharmacy, 10/14/09
Sponsor
Article Search
Sponsor